Skip to main content

Advertisement

Log in

A Phase I Study of Hyperthermic Isolated Hepatic Perfusion with Oxaliplatin in the Treatment of Unresectable Liver Metastases from Colorectal Cancer

  • Hepatobiliary and Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Isolated hepatic perfusion (IHP) is a proven approach for regional delivery of chemotherapy in patients with unresectable primary and metastatic tumors of the liver. Most trials of IHP have utilized melphalan as the active drug in the perfusate. We performed a phase I trial to evaluate the efficacy, safety, and maximum tolerated dose (MTD) of oxaliplatin delivered by hyperthermic isolated hepatic perfusion. A phase I dose-escalation trial of hyperthermic IHP with oxaliplatin in patients with unresectable metastatic colorectal cancer scheduled to undergo placement of a hepatic arterial infusion (HAI) pump was carried out. Thirteen patients were enrolled between November 2003 and September 2006. Dose-limiting veno-occlusive disease was observed at 60 mg/m2. At the MTD of 40 mg/m2 only minor transient liver dysfunction was observed. Ultrafilterable platinum area under the curve and maximum concentration delivered by IHP increased nonlinearly with dose as did platinum concentrations in liver biopsies obtained at the end of the 60 min IHP. Seventy-seven percent of patients had a >50% decrease in serum carcinoembryonic antigen (CEA) after IHP. The overall response rate to the combined IHP and HAI therapy was 66%. One patient had a durable complete response (>4 years). We conclude that hyperthermic IHP with oxaliplatin was safe and feasible at a dose of 40 mg/m2. The ability to obtain complete vascular isolation with open IHP was confirmed. The response rate in this small phase I study was encouraging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. American Cancer Society. Facts and figures 2007. Atlanta, GA; 2007.

  2. Lahr CJ, Soong SJ, Cloud G, Smith JW, Urist MM, Balch CM. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol. 1983;1(11):720–6.

    PubMed  CAS  Google Scholar 

  3. Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg. 1995;82:1397–400.

    Article  PubMed  CAS  Google Scholar 

  4. Choti MA, Bulkley GB. Management of hepatic metastases. Liver Transplant Surg. 1999;5:65–80.

    Article  CAS  Google Scholar 

  5. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.

    Article  PubMed  Google Scholar 

  6. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46(10 Suppl):S22–31.

    PubMed  Google Scholar 

  7. Ercolani G, Grazi GL, Ravaioli M, Cescon M, Gardini A, Varotti G, et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location on long-term survival. Arch Surg. 2002;137(10):1187–92.

    Article  PubMed  Google Scholar 

  8. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.

    Article  PubMed  Google Scholar 

  9. Nesbitt C, Glendinning RJ, Byrne C, Poston GJ. Factors that influence treatment strategies in advanced colorectal cancer. Eur J Surg Oncol. 2007;33(Suppl 2):S88–94.

    PubMed  Google Scholar 

  10. Kemeny N. Management of liver metastases from colorectal cancer. Oncology. 2006;20(10):1161–76, 1179.

    Google Scholar 

  11. Wicherts DA, de Haas RJ, Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol. 2007;33(Suppl 2):S42–51.

    PubMed  Google Scholar 

  12. Chun YS, Vauthey JN. Extending the frontiers of resectability in advanced colorectal cancer. Eur J Surg Oncol. 2007;33(Suppl 2):S52–8.

    PubMed  Google Scholar 

  13. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224(4):509–22.

    Google Scholar 

  14. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80.

    Article  PubMed  Google Scholar 

  15. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6(8):3062–70

    PubMed  CAS  Google Scholar 

  16. Alexander HR, Bartlett DL, Libutti SK. Isolated hepatic perfusion: A potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am. 1998;4:2–11.

    PubMed  Google Scholar 

  17. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479–89.

    PubMed  CAS  Google Scholar 

  18. Alexander HR, Bartlett DL, Fraker DL, Libutti SK, Moser T, Rosenberg SA. Results of a Phase II study of isolated hepatic perfusion (IHP) with tumor necrosis factor (TNF) and melphalan for unresectable primary or metastatic cancer confined to the liver. Proc Soc Surg Oncol. 1997;6:8. Ref Type: Abstract.

    Google Scholar 

  19. Alexander HR Jr, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol. 2005;12(2):138–44.

    Article  PubMed  Google Scholar 

  20. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129(2):176–87.

    Article  PubMed  CAS  Google Scholar 

  21. Bartlett DL, Alexander HR Jr. Isolated hepatic perfusion. In: Steele GD Jr, Phillips TL, Chabner BA, editors. Hepatobiliary cancer. Canada: B.C. Decker; 2001. p. 245–53.

    Google Scholar 

  22. de Wilt JH, van EB, Verhoef C, Eggermont AM. Isolated hepatic perfusion: experimental evidence and clinical utility. Surg Clin North Am. 2004;84(2):627–41.

    Article  PubMed  Google Scholar 

  23. Lise M, Pilati P, Da PP, Mocellin S, Ori C, Casara D, et al. Hyperthermic isolated liver perfusion for unresectable liver cancers: pilot study. J Chemother. 2004;16(Suppl 5):37–9.

    PubMed  Google Scholar 

  24. Grover AC, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T, Alexander HR Jr Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery. 2004;136(6):1176–82.

    Article  PubMed  Google Scholar 

  25. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A Phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:3062–70.

    PubMed  CAS  Google Scholar 

  26. Alexander HR Jr, Bartlett DL, Libutti SK. National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. In: Markman M, editor. Current clinical oncology: regional chemotherapy: clinical research and practice. Totowa, NJ: Humana; 2000. p. 127–50.

    Google Scholar 

  27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2002;92(3):205–16.

    Google Scholar 

  28. Erkmen K, Egorin MJ, Reyno LM, Morgan R Jr, Doroshow JH. Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother Pharmacol. 1995;35(3):254–6.

    Article  PubMed  CAS  Google Scholar 

  29. Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, et al. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res. 2002;8(9):2992–9.

    PubMed  CAS  Google Scholar 

  30. Kho Y, Jansman FG, Prins NH, Neef C, Brouwers Jr Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Ther Drug Monit. 2006;28(2):206–11.

    Article  PubMed  CAS  Google Scholar 

  31. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6(4):1205–18.

    PubMed  CAS  Google Scholar 

  32. Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Mery-Mignard D, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol. 1999;17(6):1751–9.

    PubMed  CAS  Google Scholar 

  33. Cho HK, Lee ES, Lee JW, Park JK, Kang JH, Lee KS, et al. Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. J Cancer Res Clin Oncol. 2006;132(5):320–6.

    Article  PubMed  CAS  Google Scholar 

  34. Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 2007;13(16):4832–9.

    Article  PubMed  CAS  Google Scholar 

  35. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007;13(12):3660–6.

    Article  PubMed  CAS  Google Scholar 

  36. Kern W, Braess J, Bottger B, Kaufmann CC, Hiddemann W, Schleyer E. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin Cancer Res. 1999;5(4):761–5.

    PubMed  CAS  Google Scholar 

  37. Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol. 2000;45(2):157–64.

    Article  PubMed  CAS  Google Scholar 

  38. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9(10):1053–71.

    Article  PubMed  CAS  Google Scholar 

  39. Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol. 2001;12(5):599–603.

    Article  PubMed  CAS  Google Scholar 

  40. Fiorentini G, Rossi S, Dentico P, Meucci F, Bonechi F, Bernardeschi P, et al. Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase I–II clinical study. Anticancer Res. 2004;24(3b):2093–6.

    PubMed  CAS  Google Scholar 

  41. Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H, et al. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res. 2003;23(6):5203–8.

    PubMed  CAS  Google Scholar 

  42. Mancuso A, Giuliani R, Accettura C, Palma M, D’Auria G, Cecere F, et al. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res. 2003;23(2C):1917–22.

    PubMed  CAS  Google Scholar 

  43. Meyer L, Hildebrandt B, Riess H. 5-fluorouracil, folinic acid and oxaliplatin administered via hepatic arterial infusion as regional second-line therapy for advanced colorectal cancer. Oncology. 2003;64(4):473–4.

    Article  PubMed  Google Scholar 

  44. Rietbroek RC, van de Vaart PJ, Haveman J, Blommaert FA, Geerdink A, Bakker PJ, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol. 1997;123(1):6–12.

    Article  PubMed  CAS  Google Scholar 

  45. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13(2):267–72.

    Article  PubMed  CAS  Google Scholar 

  46. van Iersel LB, Verlaan MR, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Sparidans RW, et al. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. Eur J Surg Oncol. 2007;33(7):874–81.

  47. Mocellin S, Pilati P, Da PP, Forlin M, Corazzina S, Rossi CR, et al. Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease. Ann Surg Oncol. 2007;14(2):802–9.

    Article  PubMed  Google Scholar 

  48. Yoshizumi T, Gondolesi GE, Bodian CA, Jeon H, Schwartz ME, Fishbein TM, et al. A simple new formula to assess liver weight. Transplant Proc. 2003;35(4):1415–20.

    Article  PubMed  CAS  Google Scholar 

  49. Vauthey JN, Abdalla EK, Doherty DA, Gertsch P, Fenstermacher MJ, Loyer EM, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8(3):233–40.

    Article  PubMed  Google Scholar 

  50. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow JH, et al. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. Semin Oncol. 2003;30(15):20–5.

    Article  PubMed  CAS  Google Scholar 

  51. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol. 2003;21(14):2664–72.

    Article  PubMed  CAS  Google Scholar 

  52. Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology. 2006;20(6):579–87.

    PubMed  Google Scholar 

  53. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6.

    Article  PubMed  CAS  Google Scholar 

  54. Goldberg RM, Rothenberg ML, Van CE, Benson AB, III, Blanke CD, Diasio RB, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12(1):38–50.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the University of Pittsburgh Hematology/Oncology Writing Group for constructive criticism regarding the manuscript and Dr. Jerry Collins for helpful discussions related to pharmacokinetics.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Herbert J. Zeh III MD.

Additional information

Supported, in part, by Grants from: Pittsburgh Foundation, UPMC Koch Regional Perfusion Center and NCI P30 CA47904; Oxaliplatin was supplied by Sanofi Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zeh, H.J., Brown, C.K., Holtzman, M.P. et al. A Phase I Study of Hyperthermic Isolated Hepatic Perfusion with Oxaliplatin in the Treatment of Unresectable Liver Metastases from Colorectal Cancer. Ann Surg Oncol 16, 385–394 (2009). https://doi.org/10.1245/s10434-008-0179-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-008-0179-5

Keywords

Navigation